According to drug trials, Roscovitine is a broad-spectrum purine inhibitor that competes against cyclin-dependent kinases (CDKs) for tumor treatment, while p70S6K, a protein kinase that plays an important role in tumor cells, is inhibited by PF.4708671 for anti-tumour effects (Figure 6A, B). This evidence concerns the gene RPS6KB1 and neoplasm.